New Reader for FreeStyle Libre 3; COVID Bumps Diabetes Risk; Tepezza Label Expanded

The FDA cleared a new standalone reader for the FreeStyle Libre 3 continuous glucose monitor that will help in getting the system closer to being covered by Medicare, said maker Abbott.

In a study looking at the diets of people from 184 countries, too little whole grains and too much refined rice, wheat, and processed meats were the largest dietary culprits of the global diabetes epidemic. (Nature Medicine)

Yet another study found COVID-19 infection was linked with a higher risk for developing incident diabetes within a few months. The extent of this risk was highest for males and those with severe COVID. (JAMA Network Open)

Compared with oral bisphosphonates, denosumab (Prolia, Xgeva) was linked with a lower risk for developing type 2 diabetes in adults age 45 and older with osteoporosis. (The BMJ)

The thyroid eye disease drug teprotumumab (Tepezza) is indicated for use in patients with any level of disease activity or duration according to an FDA-cleared label update, said drugmaker Horizon Therapeutics.

Functional MRIs of adolescents with overweight or obesity showed markers associated with worse cognitive function compared with adolescents with a normal BMI. (International Journal of Obesity)

Thirteen years after becoming a young pioneer for bariatric surgery, a 27-year-old women says it changed her life. (NPR)

Youth and adults with type 1 diabetes with poor glycemic control saw the most benefit from using Tandem’s hybrid-closed loop t:slim X2 Insulin Pump with Control-IQ Technology, though all patients saw a benefit, according to a meta-analysis of three randomized controlled trials. (Diabetes Technology & Therapeutics)